About Us
Group Introduction
Our History
Hans Biomed Co. is a global leader that leverages innovative R&D technology to create groundbreaking solutions found nowhere else in the world. Our commitment to advancing medical treatments and technology related to regenerative medicine and tissue engineering is at the forefront of our mission.
Our efforts have been the driver of our global expansion beyond South Korea, and we now have seven overseas subsidiaries and numerous local branch offices. Hans Biomed USA, Inc. was founded in 2011 and is recognized as a best-in-class aesthetic company and pioneer in the aesthetic and biologics industry.
At Hans Biomed USA, our mission is to embrace new challenges in the pursuit of improving the quality of life for all of humanity through revolutionary R&D in biotechnology.
We work hand in hand with healthcare providers and patients to deliver safe, innovative, and meaningful treatments that help people around the world live longer, healthier lives.
Establishing Korea's
First Tissue Bank
In 2005, we achieved a significant milestone by obtaining approval from the Ministry of Food and Drug Safety (MFDS) to establish Korea’s very first tissue bank.
Despite the presence of numerous companies, research institutions, and universities engaged in tissue engineering, we became the first entity in Korea to receive this authorization. This was achieved because of our aptitude for maintaining state-of-the-art facilities staffed by highly skilled professionals, where stringent quality control is necessary for proper sterility and aseptic conditions of a tissue bank.
Selected as "World Top-Class Product Company"
In both 2002 and 2010, Hans Biomed Co. was honored with the prestigious “World Top-Class Product Company” award, sponsored by the Ministry of Commerce, Industry, and Energy.
This recognition underscores our position as an outstanding export-oriented venture company, marking a historic achievement as the first company specializing in human tissue transplants to receive this accolade.
State-Of-The-Art Research Laboratory
Hans Daeduk Research Center, representing an investment of 6 billion KRW, occupies a site of 11,900m² (initially 2,644m² but later expanded to 5,950m²) and is equipped with advanced research units and production facilities.
The research lab achieved a significant milestone by successfully commercializing the technology for processing acellular dermis using human transplant tissues, marking the first such success in Korea and the second worldwide. This achievement has positioned Hans Biomed as a leader in tissue engineering technology within Korea, showcasing our unparalleled competitive edge.
Our commitment extends beyond national borders as we strive to elevate the domestic tissue engineering industry to international standards, safeguard national health interests, and reduce reliance on imports. We are dedicated to distributing our products both within Korea and to overseas markets, contributing to the advancement of healthcare worldwide.
First in the Industry to be Listed on KOSDAQ
Hans Biomed became the first company in its industry to be listed on KOSDAQ in October 2009, marking its transformation into a genuine global enterprise. This feat was made possible through strategic investments and the recruitment of top-tier talent, which further enhanced our competitive edge.
Notably, our skin and bone transplants, renowned for their exceptional technology and quality, have been gradually replacing foreign products in the market. However, our ambitions extend beyond import substitution, as we actively export these products to various regions, including South America, Asia, the Middle East, as well as the United States and Europe.
